Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
Portfolio Pulse from Vandana Singh
Moderna Inc. (NASDAQ: MRNA) received FDA approval for its second mRNA product, mRESVIA, an RSV vaccine for adults aged 60 and older. This approval, under a breakthrough therapy designation, follows the company's COVID-19 vaccine. The approval is based on strong Phase 3 clinical trial results showing high efficacy. Moderna aims to have the vaccine available by the 2024/2025 respiratory virus season. The company reaffirms its 2024 sales expectations of around $4 billion.
May 31, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna received FDA approval for its RSV vaccine, mRESVIA, marking its second mRNA product. The approval is based on strong Phase 3 trial results and aims to address a significant health issue among older adults. This approval could help offset declining COVID-19 vaccine sales.
The FDA approval of mRESVIA is a significant milestone for Moderna, showcasing the versatility of its mRNA platform. The high efficacy rates from the Phase 3 trial and the potential to address a major health issue among older adults could positively impact Moderna's revenue streams, especially as COVID-19 vaccine sales decline.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100